AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - Table II. Rubella to Salmonellosis

NNDSS - Table II. Rubella to Salmonellosis - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.    NP: Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
HIV-1 expression induces cyclin D

Background
          The aberrant cell-cycle progression of HIV-1-infected kidney cells plays a major role in the pathogenesis of HIV-associated nephropathy, however the mechanisms whereby HIV-1 induces infected glomerular podocytes or infected tubular epithelium to exit quiescence are largely unknown. Here, we ask whether the expression of HIV-1 genes in infected podocytes induces cyclin D1 and phospho-pRb (Ser780) expression, hallmarks of cyclin D1-mediated G1 → S phase progression.
        
        
          Results
          We assessed cyclin D1 and phospho-pRb (Ser780) expression in two well-characterized models of HIV-associated nephropathy pathogenesis: HIV-1 infection of cultured podocytes and HIV-1 transgenic mice (Tg26). Compared to controls, cultured podocytes expressing HIV-1 genes, and podocytes and tubular epithelium from hyperplastic nephrons in Tg26 kidneys, had increased levels of phospho-pRb (Ser780), a target of active cyclin D1/cyclin-dependent kinase-4/6 known to promote G1 → S phase progression. HIV-1-infected podocytes showed markedly elevated cyclin D1 mRNA and cyclin D1 protein, the latter of which did not down-regulate during cell-cell contact or differentiation, suggesting post-transcriptional stabilization of cyclin D1 protein levels by HIV-1. The selective suppression of HIV-1 transcription by the cyclin-dependent kinase inhibitor, flavopiridol, abrogated cyclin D1 expression, underlying the requirement for HIV-1 encoded products to induce cyclin D1. Indeed, HIV-1 virus deleted of nef failed to induce cyclin D1 mRNA to the level of other single gene mutant viruses.
        
        
          Conclusions
          HIV-1 expression induces cyclin D1 and phospho-pRb (Ser780) expression in infected podocytes, suggesting that HIV-1 activates cyclin D1-dependent cell-cycle mechanisms to promote proliferation of infected renal epithelium.
Predominance of CIN versus MSI in the development of rectal cancer at young age

Background
          Development of proximal and distal colorectal cancers involve partly different mechanisms associated with the microsatellite instability (MSI) and the chromosomal instability (CIN) pathways. Colorectal cancers in patients under 50 years of age represent about 5% of the total number of tumors and have been associated with an increased frequency of MSI tumors. However, MSI and CIN may play different roles in the development of colon cancer and rectal cancer, and we have specifically investigated their contribution to the development of rectal cancer at young age.
        
        
          Methods
          Thirty rectal cancers diagnosed before the age of 50 were characterized for DNA-ploidy, MSI, mutations of KRAS and CTNNB1 and immunohistochemical expression of p53, β-catenin and of the mismatch repair (MMR) proteins MLH1 and MSH2.
        
        
          Results
          DNA aneuploidy was detected in 21/30 tumors, KRAS mutations in 6 tumors, no mutations of CTNNB1 were detected but immunohistochemical staining for β-catenin showed nuclear staining in 6 tumors, and immunohistochemical expression of p53 was detected in 18 tumors. MSI was detected in 3/30 tumors, all of which showed and immunohistochemical loss of staining for the MMR protein MSH2, which strongly indicates a phenotype associated with hereditary nonpolyposis colorectal cancer (HNPCC).
        
        
          Conclusions
          MSI occurs only in a small fraction of the tumors from young patients with rectal cancer, but when present it strongly indicates an underlying HNPCC-causing mutation, and other mechanisms than HNPCC thus cause rectal cancer in the majority of young patients.
Compound 529145: 1-Dodecanamine, mono-DMTBS

Chemical compound data from PubChem database. IUPAC Name: N-[tert-butyl(dimethyl)silyl]dodecan-1-amine. Molecular Formula: C18H41NSi. Molecular Weight: 299.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Survey of Substance Abuse Treatment Services (N-SSATS-2011)

<p>The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment<br />
Facility Locator <a href="http://findtreatment.samhsa.gov">http://findtreatment.samhsa.gov</a>, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.</p>
Hospital Cost Report Audited Data Print Image: 2022

This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/
Program Instruction (PI-15-02)

This Program Instruction (PI) provides instruction on the availability of Federal Fiscal Year (FFY) 2015 funds under the Community-Based Grants for the Prevention of Child Abuse and Neglect program created by Title II of the Child Abuse Prevention and Treatment Act (CAPTA) as amended by Public Law (P.L.) 111-320.

Metadata-only record linking to the original dataset. Open original dataset below.
Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial [ISRCTN19943732]

The Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial is a multicentre,randomised, placebo-controlled trial of magnesium sulphate (MgSO4) funded by the UK Medical Research Council. When complete, it will be the largest single neuroprotective study undertaken to date. Conscious patients presenting within 12 h of acute stroke with limb weakness are eligible. The primary outcome measure is combined death and disability as measured using the Barthel Index at 90-day follow up. By randomizing 2700 patients, the study will have 84% power to detect a 5.5% absolute reduction in the primary end-point. By April 2000, 86 centres were participating, with representation in Canada, USA, Europe, South America, Singapore and Australia. So far, 1206 patients have been randomised, of whom 37% were treated within 6 h. Overall 3-month mortality was 20% and the primary outcome event rate was 43%. The study is ongoing and centres worldwide are encouraged to participate.
Compound 528472: 2,6-Dimethyl-2-dodecene

Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethyldodec-2-ene. Molecular Formula: C14H28. Molecular Weight: 196.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526950: 4-Methylfuran-2-carbaldehyde

Chemical compound data from PubChem database. IUPAC Name: 4-methylfuran-2-carbaldehyde. Molecular Formula: C6H6O2. Molecular Weight: 110.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400057-T1: [Translated] USE OF HIGH PERFORMANCE DIELECTRIC OIL FOR HIGH VOLTAGE ELECTRICAL EQUIPMENT

The invention relates to a high-performance dielectric oil comprising approximately 75 to 95% by volume of a naphthenic oil and approximately 5 to 25% by volume of an ester oil, in particular a synthetic ester oil and more preferably an oil of the family of polyolesters. The high-performance dielectric oil may be used in high-voltage electrical equipment such as power, measurement, distribution or traction transformers, tap changers, bushings, distributors, oil-immersed circuit breakers, power capacitors, cables, etc.
NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b

NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases

Background:
          Protein fold recognition using sequence profile searches frequently allows prediction of the structure and biochemical mechanisms of proteins with an important biological function but unknown biochemical activity. Here we describe such predictions resulting from an analysis of the 2-oxoglutarate (2OG) and Fe(II)-dependent oxygenases, a class of enzymes that are widespread in eukaryotes and bacteria and catalyze a variety of reactions typically involving the oxidation of an organic substrate using a dioxygen molecule.
        
        
          Results:
          We employ sequence profile analysis to show that the DNA repair protein AlkB, the extracellular matrix protein leprecan, the disease-resistance-related protein EGL-9 and several uncharacterized proteins define novel families of enzymes of the 2OG-Fe(II) oxygenase superfamily. The identification of AlkB as a member of the 2OG-Fe(II) oxygenase superfamily suggests that this protein catalyzes oxidative detoxification of alkylated bases. More distant homologs of AlkB were detected in eukaryotes and in plant RNA viruses, leading to the hypothesis that these proteins might be involved in RNA demethylation. The EGL-9 protein from Caenorhabditis elegans is necessary for normal muscle function and its inactivation results in resistance against paralysis induced by the Pseudomonas aeruginosa toxin. EGL-9 and leprecan are predicted to be novel protein hydroxylases that might be involved in the generation of substrates for protein glycosylation.
        
        
          Conclusions:
          Here, using sequence profile searches, we show that several previously undetected protein families contain 2OG-Fe(II) oxygenase fold. This allows us to predict the catalytic activity for a wide range of biologically important, but biochemically uncharacterized proteins from eukaryotes and bacteria.
Are statins anti-inflammatory?

Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may be larger in these trials than that expected on the basis of lipid lowering alone. Emerging evidence from both clinical trials and basic science studies suggest that statins have anti-inflammatory properties, which may additionally lead to clinical efficacy. Measurement of markers of inflammation such as high sensitivity C-reactive protein in addition to lipid parameters may help identify those patients who will benefit most from statin therapy.
2012 Uniform Reporting System (URS) Tables for Colorado

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Program Instruction (PI-20-02)

This Program Instruction (PI) provides guidance to states, territories, and insular areas (hereafter “states,” unless otherwise noted) on actions they are required to take to receive their allotments for Federal Fiscal Year (FY) 2021 (subject to the availability of appropriations) authorized under title IV-B, subparts 1 and 2, section 106 of CAPTA, Chafee and ETV programs.

PI-20-02  (PDF)

Fiscal Year 2019 Allotment Title IV-B Subpart 1 Stephanie Tubbs Jones Child Welfare Services
Fiscal Year 2019 Allotment Title IV-B Subpart 2 Promoting Safe and Stable Families
Fiscal Year 2019 Allotment for Title IV-B, Subpart 2 Monthly Caseworker Visit Funds
Fiscal Year 2019 Allotment for CAPTA
Fiscal Year 2019 Allotment for Chafee Foster Care Program for Successful Transition to Adulthood 
Fiscal Year 2019 Allotment for Education and Training Vouchers

CFS-101 Instructions, Part I, II, and III

Introduction
Part I: Annual Budget Request for Title IV-B, Subpart 1 & 2 Funds, CAPTA, Chafee, and ETV Instructions
Part II: Annual Estimated Expenditure Summary of Child and Family Services Instructions
Part III: Expenditures for Title IV-B, Subparts 1 and 2, Chafee Foster Care Program for Successful Transition to Adulthood (Chafee) and Education and Training Voucher (ETV) Programs Instructions

CFS-101 Forms, Parts I, II and III Excel Workbook  (XLSX)(41 KB)

CFS-101 Forms Part I
CFS-101 Forms Part II
CFS-101 Forms Part III

CB Regional Program Managers

Annual Reporting of Education and Training Vouchers Awarded (PDF (PDF) - 83 KB)

Metadata-only record linking to the original dataset. Open original dataset below.
Number of Cancer Cases for All Cancer Sites by Jurisdiction, Gender, and Race, Maryland 2009

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated 8/14/2024. 

Definition of "All Cancer Sites": ICD-O-3 Topography (Site) Codes  C00.0 – C80.9  with histology codes including all invasive cancers of all sites except basal and squamous cell skin cancers, and in situ cancer cases of the urinary bladder.  Total includes cases reported as transexual, hermaphrodite, and unknown gender.  Some cells are missing data due to suppression of low cell counts.
Compound 529384: Propenyl trisulfide

Chemical compound data from PubChem database. IUPAC Name: 1-(prop-1-enyltrisulfanyl)prop-1-ene. Molecular Formula: C6H10S3. Molecular Weight: 178.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525325: Pyrazolo[1,5-d][1,2,4]triazin-3-one, 2,5,6-trimethyl-7-phenyl

Chemical compound data from PubChem database. IUPAC Name: 2,5,6-trimethyl-7-phenyl-7H-pyrazolo[1,5-d][1,2,4]triazin-4-one. Molecular Formula: C14H16N4O. Molecular Weight: 256.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399749-T1: [Translated] METHOD FOR HYDROGENATION OF METHYLOLALAL CHANNELS

Disclosed is a method for the catalytic hydrogenation of methylol alkanals of general formula (I), where R<SUP>1 </SUP>and R<SUP>2 </SUP>independently represent an additional methylol group or an alkyl group having with 1 to 22 carbon atoms, or an alkyl group with 1 to 22 C atoms, or an aryl group or aralkyl group with 6 to 33 carbon atoms, in the liquid phase on a hydrogenation catalyst. The inventive method is characterized in that a pH value ranging between 6.3 and 7.8 is adjusted in the hydrogenation feed by adding at least one tertiary amine
Weekly Cumulative Percentage of Adults 60 Years and Older Vaccinated with Respiratory Syncytial Virus (RSV) Vaccine by Jurisdiction

Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Jurisdiction 

• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html) 

• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)
Patent AT-E400656-T1: [Translated] MINI-DYSTROPHIN NUCLEIC ACID AND PEPTIDE SEQUENCES

The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.
Compound 525445: 3-Ethyl-2,4-dithiapentane

Chemical compound data from PubChem database. IUPAC Name: 1,1-bis(methylsulfanyl)propane. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527326: Methyl 2-(5,6-dimethoxynaphthalen-2-yl)propanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-(5,6-dimethoxynaphthalen-2-yl)propanoate. Molecular Formula: C16H18O4. Molecular Weight: 274.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Federal Fiscal Year 2024 Title IV-B, Subpart 2 Funding Available to Develop and Enhance or to Evaluate Kinship Navigator Programs

This Program Instruction (PI) provides guidance to state, territorial and Tribal title IV-E agencies on the actions required to apply for title IV-B, subpart 2 funding to support the development, enhancement or evaluation of kinship navigator programs. These are federal fiscal year (FY) 2024 funds, provided in the Further Consolidated Appropriations Act, 2024.

For the best usability of Attachment B, please download the file and save it to your computer.

Metadata-only record linking to the original dataset. Open original dataset below.